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Abstract
Background: CRP gene polymorphisms are associated with serum C-reactive protein concentrations and may play
a role in chronic kidney disease (CKD) progression. We recently reported an association between the gene variant
rs2808630 and CKD progression in African Americans with hypertensive kidney disease. This association has not
been studied in other ethnic groups.
Methods: We used data from 5955 participants from Phase 2 of The Third National Health and Nutrition
Examination Survey (1991-1994) to study the association between CRP polymorphisms and CKD prevalence in a
population-based sample. The primary outcome was CKD defined as estimated glomerular filtration rate (eGFR) <60
ml/min or the presence of albuminuria. Secondary outcomes were the presence of albuminuria (any degree) and
continuous eGFR. Six single nucleotide polymorphisms (SNPs) from the CRP gene, rs2808630, rs1205, rs3093066,
rs1417938, rs3093058, and rs1800947, were evaluated.
Results: CRP rs2808630 AG compared to the referent AA genotype was associated with CKD in non-Hispanic
blacks (n = 1649, 293 of whom had CKD) with an adjusted odds ratio (OR) of 3.09 (95% CI 1.65-5.8; p = 0.001). For
the secondary outcomes, rs2808630 AG compared to the referent AA genotype was associated with albuminuria
with an adjusted OR of 3.07 (95% CI 1.59-5.94; p = 0.002), however not with eGFR. There was no association
between the SNPs and CKD, albuminuria or eGFR in non-Hispanic whites or Mexicans Americans.
Conclusions: In this cross-sectional study, the 3’ flanking CRP gene variant rs2808630 was associated with CKD,
mainly through its association with albuminuria in the non-Hispanic blacks. Despite not finding an association with
eGFR, our results support our previous study demonstrating an association between CRP gene variant rs2808630
and CKD progression in a longitudinal cohort of African American with hypertensive kidney disease.
Background
Chronic kidney disease (CKD) represents a major public
health problem worldwide. Even in its early stages, CKD
is associated with poor outcomes and premature death
mainly due to cardiovascular causes [1,2]. Familial
aggregation of CKD and end stage renal disease (ESRD)
have been reported in populations throughout the world
for all types of nephropathy, underscoring the impor-
tance of genetic factors [3-7]. There also appears to be
genetic predisposition towards faster progression to
ESRD which is strongly associated with race. For exam-
ple, African Americans with a first degree relative with
E S R Dh a v ea9 - f o l di n c r e a s ei nt h er i s ko fE S R Dc o m -
pared to a 3-5 fold increase in whites [8,9]. Recently,
genetic variations in two candidate genes both located
within a 60 kb region of chromosome 22 have been
identified as high risk for non-diabetic ESRD in African
Americans[10]: the nonmuscle myosin heavy chain 9
(MYH9)[9] and the apolipoprotein L1 (APOL1)[10]
genes. It is possible that additional genetic variants, such
as those related to inflammatory pathways, may also be * Correspondence: Adriana.hung@vanderbilt.edu
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pathways and the risk of ESRD in general.
CKD is an inflammatory process, and biomarkers of
inflammation increase as kidney function declines
[11,12]. Previous studies have shown that inflammation-
related gene polymorphisms explain a proportion of
trait variability observed for these biomarkers [1,13-19].
Given this relationship, it is likely that inflammation-
related gene polymorphisms are also associated with
CKD progression. We have previously demonstrated an
association between a single nucleotide polymorphism
rs2808630 in the CRP gene and CKD progression in the
prospective African American Study of Kidney Disease
and Hypertension (AASK) study [11], a randomized
control trial designed to evaluate the effect of three dif-
ferent antihypertensive medications in the progression
of hypertensive kidney disease [20]. In addition to being
associated with decreased levels in general African
American populations [15,17], this SNP has been asso-
ciated with decreased CRP in the AASK study [11] sug-
gesting that the relationship between CKD and
inflammation is complex and can be influenced by
genetic factors.
In the current study, we used genetic data from the
Third National Health and Nutrition Examination Sur-
vey (NHANES III), a large population-based survey, to
further investigate our findings in non-Hispanic blacks,
non-Hispanic whites and Mexican Americans. The pri-
mary goal of this study was to test the association
between six CRP SNPs and the presence of CKD defined
as either estimated glomerular filtration rate (eGFR) <60
ml/min/m
2 or the presence of albuminuria according to
National Kidney Foundation (NKF) consensus defini-
tions [21]. Additionally, we evaluated the association
between these polymorphisms with albuminuria (any
degree) and continuous eGFR.
Methods
Study Population
The NHANES are surveys conducted by the National
Center for Health Statistics (NCHS) at the Centers for
Disease Control and Prevention (CDC) to provide
national estimates of the health and nutrition of the U.S.
civilian, non-institutionalized population. NHANES III is
a complex, multistage survey that oversampled minori-
ties (non-Hispanic blacks and Mexican Americans), chil-
dren, and the elderly. Sample weights are provided for
each participant included in the survey to correct for
non-response and to correct for the fact that each parti-
cipant was not selected for the survey with equal prob-
ability. Participants were consented by the CDC at the
time of the survey and sample collection, and consent
included the storage of data and biological specimens
for future research [22].
DNA samples were generated using cell lines created
from blood samples of participants older than 12 years
of age during NHANES III phase 2 (1991-1994). The
total number of participants in NHANES III phase 2
was 16,530 and DNA was available for 7,159 partici-
pants. To account for this difference in DNA availability,
the sample weights were recalculated using previously
described methods [15]. All participants with DNA
available had completed a household interview and a
physical examination in the Mobile Examination Center.
We excluded participants younger than 18 years of
age (n = 979) as the modification of diet in renal disease
(MDRD) equation is not applicable to them, 35 partici-
pants with missing serum creatinine concentrations, 71
participants with missing albuminuria measurements
and normal kidney function, and 119 pregnant women.
Our exclusion criteria were similar to other studies in
general [23,24]. However we allowed participants age
18-20 years of age in the cohort, (different from other
studies in the NHANES population [23,24]) as they are
usually included in studies of CKD progression [25,26]
and the MDRD equation applies to them. After exclu-
sion criteria were applied, our final analysis included
data from 5955 participants. The study protocol was
reviewed and approved by the Center of Disease Control
(CDC) Ethical Review Board. Because the study investi-
gators did not have access to personal identifiers, the
Vanderbilt University Internal Review Board and the VA
Tennessee Valley Healthcare System approved the pro-
tocol as non-human subject research under the exempt
category.
Measurements and Definitions
The primary outcome for this study was CKD defined
as either an eGFR <60 ml/min or the presence of albu-
minuria in accordance to the NKF consensus definition
which classifies all individuals with evidence of kidney
damage (e.g. albuminuria) as having chronic kidney dis-
ease, irrespective of the level of GFR [21]. The focus of
our study was to identify SNPs associated with common
pathways for advanced CKD, and albuminuria is one of
the main risk factors for CKD progression [2,27]. Sec-
ondary outcomes were a) albuminuria defined using
sex-specific cut-offs of urine albumin creatinine ratio
(ACR) ≥ 17 mg/g for men and ≥ 25 mg/g for women
[24,28,29] and b) continuous eGFR. The choice of ana-
lyzing eGFR as a continuous trait was made to maxi-
mize the information available in the dataset, as there
was a small number of participants with low GFR. We
also performed an sensitivity analysis where eGFR was
dichotomized as < or ≥ 60 ml/min.
NHANES creatinine was calibrated to the creatinine
values of the Cleveland Clinic Laboratory [creatinine
calibration formula: MDRDcr = -0.184 + 0.96 *NHANES
III uncalibrated creatinine]. eGFR was calculated using
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1.73 m2) = 175 × (serum creatinine)
-1.154 × (Age)
-0.203 ×
(0.742 if female) × (1.210 if African American). Calibra-
tion formula: MDRDcr = -0.184 + 0.96 *NHANES III
uncalibrated creatinine. Urine albumin and creatinine
were measured from a single random morning voided
urine sample. Samples were obtained by a clean catch
technique and shipped overnight on dry ice to a central
laboratory and frozen for a later use. Urine albumin
concentration was measured by means of solid-phase
fluorescent immunoassay. Urine creatinine concentra-
tion was measured using the Jaffé method. Urine albu-
min creatinine ratio (ACR) is expressed in units of
milligrams per gram. Similarly, CKD stages were cate-
gorized based on the current NKF classification system.
Genotype data
As previously reported, the CRP gene (2.3 kb) is located
on chromosome 1q21-1q23. We accessed the genotype
data for six CRP SNPs (rs1417938, rs1205, rs1800947
(Leu184Leu), rs2808630, rs3093058, and rs3093066)
through the NHANES Genetic database maintained by
the National Center for Health Statistics at the Centers
for Disease Control and Prevention. All six SNPs
selected were previously genotyped by Crawford et al
[15] using Applied Biosystems TaqMan and Epoch
MGB Eclipse Probe Systems (rs1800947). As previously
reported [15], the overall average SNP genotyping call
rate was 95%, and no SNP was out of Hardy Weinberg
Equilibrium at p < 0.001 in all three subpopulations
tested
Covariate Definitions
We ascertained known risk factors for CKD using
NHANES measurements. Race/ethnicity was self-
assigned as non-Hispanic white, non-Hispanic black,
Mexican American, or other. C-reactive protein (CRP)
assay used in for NHANES was a low sensitivity assay,
with a lower limit of detection of 0.22 mg/dL. CRP
values were right skew and were log transformed for the
analysis. Diabetes mellitus (DM) was defined as a self-
reported physician diagnosis of diabetes, use of diabetes
medications (insulin or pills for diabetes), a plasma glu-
cose from-first venipuncture >126 mg/dl or a random
glucose from the biochemistry profile > 200 mg/dl.
Hypertension was defined as any use of antihypertensive
medications, the average of two systolic blood pressure
measurements of 140 mm Hg or greater, or diastolic
b l o o dp r e s s u r eo f9 0m mH go rg r e a t e rt a k e nd u r i n g
the examination. Smoking status was defined as “cur-
rent” if the participant answered “yes” to the question
“do you smoke now” or if the participant had cotinine
levels >15 ng/mL. Body mass index (BMI) was classified
as obese (≥30 kg/m
2) or not obese. Triglycerides,
calculated LDL cholesterol, and HDL cholesterol were
treated as continuous variables. Cardiovascular disease
(CVD) was considered positive if the participant
reported ever having been told that he or she had had a
heart attack, heart failure, or stroke or had undergone a
surgical or percutaneous procedure for any of these
conditions.
Statistical analysis
All results were weighted to account for the sampling
design of NHANES III, which were recalculated by the
CDC for NHANES III genetic study. All analyses were
stratified by self reported race/ethnicity. Unadjusted and
adjusted logistic regressions were conducted assuming
an additive genetic model for each SNP (that is, with a
change in the odds ratio or beta-coefficient per copy of
the minor allele). Our prior research indicated that
minor allele “G” is the “at-risk” allele for CKD progres-
sion compared with the major allele “A”.H e n c e ,S N P s
were treated as categorical variables and coded as fol-
lows: 0 = homozygous major, 1 = heterozygous, and 2 =
homozygous minor; the homozygous major category
was considered the reference level. The primary out-
come was CKD (any stage of CKD) treated as a binary
outcome given the small number of participants with
advance stages of CKD 4-5. For the secondary out-
comes, continuous GFR was log transformed. Albumi-
n u r i aw a sd e f i n e da sab i n a r yo u t c o m e( a n yd e g r e eo f
albuminuria). All analyses were performed either remo-
tely using the Analytic Data Research by Email
(ANDRE) portal of the CDC Research Data Center
(RDC) in Hyattsville, MD or in person at the RDC using
STATA 10 MP(College Station, TX), SAS/Genetics 9.1.3
(SAS Institute, Cary, NC), and SUDAAN 10 (Research
Triangle Institute, NC). Our power calculation was
focused in the association of the rs2808630 polymor-
phims and CKD in African Americans, based in our pre-
vious study (12) with a minor allele frequency of 0.14
for NHANES III. We estimated that we needed 253
African Americans with CKD and 253 African Ameri-
cans without CKD in order to detect a genotype risk of
1.6 or higher, using an additive model. This model was
chosen base in our previous study (12). Additionally
given our small sample of African Americans with CKD
(n = 293) we estimated that we will be under power for
a dominant model requiring at least 354 controls and
cases for the same genotype risk. We considered signifi-
cance for a two sided alpha of 0.05 for all analyses and
Bonferroni-adjusted alpha of 0.002 (0.05/29).
Results
Participants’ characteristics are shown in table 1. From
the 5955 participants that met criteria for our study, a
total of 1,175 (20%) qualified as having CKD. More
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60 ml/min and 16% (n = 961) had albuminuria. Chronic
kidney disease patients were older, 81% (n = 951) had
albuminuria, had a higher prevalence of diabetes mellitus,
hypertension, cardiovascular disease, higher body mass
index, higher CRP levels, and lower smoking exposure
compared to participants without CKD. Genotype fre-
quencies by race/ethnicity are displayed in table 2. There
were no statistically significant differences in the clinical
characteristics among the different race/ethnicity groups
by CKD status (additional file 1, table S1). Genotype fre-
quencies by race for participants with and without CKD
are displayed in table 2. Genotype frequencies by race for
participants with and without albuminuria are displayed
in additional file 1 table S4.
CRP genotypes and CKD defined as either by the
presence of albuminuria or low GFR
Among non-Hispanic blacks, rs2808630 was associated
with CKD both in the unadjusted (table 3) and adjusted
analysis (table 4). More specifically, the AG genotype had
an unadjusted odds ratio of 1.68 (95% CI: 1.34-2.12; p =
0.0001) for the presence of CKD compared to the AA gen-
otype (table 3). Similarly the AG genotype was associated
with CKD with an odds ratio of 2.94 (95% CI: 1.61 to 5.38;
p = 0.001) compared to the AA genotype for the fully
adjusted model, for other known risk factors for CKD.
Both of these associations remained significant even after
Bonferroni adjustment for the significance level (p ≤
0.002). This significant association did not change when
adjusting for CRP (table 4). Other independent predictors
Table 1 Characteristics of the study participants ≥ 18 years of age, NHANES III DNA bank, 1991-1994, stratified by
chronic kidney disease (CKD) status
Characteristics Total (n = 5955) § CKD (n = 1175) No CKD (n = 4780) p-value
Age, median (IQR) years 42 (30, 62) 67 (48,77) 38 (28,48) <0.0001
Gender (males) (%) 44 42 44 0.01
Race/Ethnicity (%) 0.02
Non-Hispanic White % (n) 39% (2338) 47% (556) 37% (1782)
Non-Hispanic Black % (n) 28% (1649) 25% (293) 28% (1356)
Mexican American % (n) 28% (1685) 23% (272) 30% (1413)
Others % (n) 5% (283) 5% (54) 5% (229)
Serum Creatinine, mg/dL, median (IQR) 1 (0.9, 1.2) 1.2 (1,1.4) 1 (0.9,1.2) <0.0001
Median eGFR ml/min/1.73 m2 (IQR) 93 (78, 109) 66 (53,87) 88 (77,104) <0.0001
Urine albumin to creatinine ratio (IQR) 5.38 (2.66, 11.79) 35 (17, 87) 4 (21,74) <0.0001
Albuminuria <0.0001
None, % (n) 84% (5004) 19% (224) 100% (4780)
Microalbuminuria, % (n) 14% (813) 69%(813) 0 (0)
Macroalbuminuria, % (n) 2% (138) 12%(138) 0 (0)
Any form of albuminuria, % (n) 16% (951) 81%(951) 0 (0)
Low GFR
GFR < 60 ml/min (%) 7 35 0 <0.0001
CKD stage III (eGFR 30-59 ml/min) (%) 6.5 3 0
CKD stage IV (eGFR 15-29 ml/min) (%) 0.4 1 0
CKD stage V (eGFR < 15 ml/min) (%) 0.1 1 0
Systolic BP median (IQR), mmHg 119 (108, 134) 136 (120, 155) 117 (108,129) <0.0001
Diastolic BP median (IQR), mmHg 62 (64, 80) 74 (66, 83) 72 (65,79) 0.07
Hypertension, % 22 46 15 <0.0001
BMI, median (IQR) 26.5 (23, 30) 27 (24, 31) 26 (23, 30) 0.02
C-reactive protein level (%) <0.0001
<0.22 mg/dl (%) 62 53 65
0.22-0.99 mg/dl (%) 29 34 27
>1.00 mg/dl (%) 9 13 7
Current Smoking (%) 20 18 19 0.002
Prevalent CHD, (%) 8 19 4 <0.0001
LDL median (IQR),, mg/dL 122 (99, 146) 133 (106, 157) 120 (98, 144) 0.13
Diabetes (%) 11 26 7 <0.0001
*Categorical variables were tested using the Cochran-Mantel-Haenszel Test and continuous variables were tested using the Taylor Linearization method with
SUDAAN. All tests were weighed.
§ CKD defined as either by decrease glomerular filtration rate (eGFR) or by the presence of albuminuria
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SNP rs2808630 rs1205 rs1800947* rs3093058 rs3093066 rs1417938
Location 3’ flanking region 3’ flanking region Exon 2 5’ flanking region 5’ flanking region Intron 1
Genotypes AA AG GG GG AG AA GG CG CC AA AT TT CC AC AA AA AT TT
Non-Hispanic Whites
N 270 221 43 241 236 57 475 ** ** 537 5 - 498 9 - 259 239 48
CKD, GFP 50.75 42.68 6.57 46.17 42.19 11.63 93.19 ** ** 98.36 1.64 - 97.69 2.31 - 47.44 43.7 8.79
N 867 686 133 694 808 190 1544 ** ** 1718 6 - 1610 15 - 851 730 148
No-CKD,GFP 52.13 40.38 7.49 42.16 46.51 11.33 94.43 ** ** 99.55 0.45 - 98.94 1.06 - 49.22 42.22 8.56
Non-Hispanic Blacks
rs2808630 rs1205 rs1800947* rs3093058 rs3093066 rs1417938
N 181 96 8 190 86 9 ** ** - 212 71 8 154 105 15 221 62 **
CKD, GFP 61.45 36.4 2.14 67.06 29.39 3.55 99 ** - 76.01 22.89 1.1 56.35 38.37 5.28 77.75 20.65 **
N 950 323 26 804 397 79 ** ** - 915 356 34 751 443 67 1024 272 21
No-CKD,GFP 72.24 25.42 2.34 62.68 31.26 6.06 99 ** - 69.67 27.66 2.67 60.67 34.12 5.21 77.54 21.75 0.4
Mexicans Americans
rs2808630 rs1205 rs1800947* rs3093058 rs3093066 rs1417938
N 167 89 11 102 137 31 253 7 - 260 8 ** 269 ** ** 110 130 24
CKD, GFP 61.12 33.75 5.13 42.21 47.09 10.70 97.66 2.3 - 95.81 3.91 ** 99.25 ** ** 41.67 49.23 9.1
N 852 434 57 562 621 168 1266 54 - 1348 37 ** 1308 ** ** 591 616 155
No-CKD,GFP 62.48 33.04 4.48 41.65 45.65 12.7 95.6 4.4 - 97.08 2.92 ** 96.59 ** ** 43.39 45.23 11.3
** Data user agreement with the CDC does not allow outputs with counts less than 5.
N: number of individuals with the specific genotype. GFP: genotype frequency percent
Table 3 Unadjusted and weighed association of CRP gene polymorphism and CKD, additive genetic model
Presence of CKD (logistic regression) for each SNP
No No No
Non-Hispanic Whites ¥ p value Non-Hispanic Blacks ¥ p value Mexican American ¥ p value
rs2808630
AA 1137 ref 1131 ref 1019 Ref
AG 907 1.09 (0.78-1.52) 0.6 419 1.68 (1.34 - 2.12) 0.0001* 523 1.04(0.58-1.88) 0.9
GG 176 0.90 (0.52-1.57) 0.7 34 1.08 (0.43 - 2.71) 0.9 68 1.17(0.57-2.40) 0.7
rs1205
GG 935 ref 994 ref 664 Ref
AG 1044 0.88 (0.61-1.28) 0.5 483 1.60 (0.66-3.88) 0.3 758 1.22 (0.76-1.97) 0.4
AA 247 1.07 (0.77-1.48) 0.7 88 1.82 (0.82-4.06) 0.1 199 1.20(0.77-1.89) 0.4
rs1417938
AA 1110 ref 1245 ref 701 Ref
AT 969 1.07 (0.76-1.50) 0.7 334 1.08(0.080-1.44) 0.6 746 1.21 (0.92-1.58) 0.2
TT 196 1.08 (0.61-1.93) 0.8 23 0.43(0.09-1.99) 0.3 179 1.10 (0.48-2.50) 0.8
rs1800947
GG 2019 ref 1508 ref 1519 Ref
CG ** 1.21 (0.56 - 2.66) 0.6 20 0.55 (0.13-2.26) 0.4 61 0.52 (0.20-1.38) 0.2
rs3093058
AA 2255 ref 1127 ref 1608 Ref
AT 11 3.69 (0.74-18.44) 0.09 427 0.76 (0.60-0.96) 0.02 ** 1.36 (0.59-3.15) 0.5
TT - _ 42 0.38 (0.13-1.07) 0.07 ** _
rs3093066
CC 2108 ref 905 ref 1577 Ref
CA 24 2.20 (0.65-7.47) 0.2 548 1.11 (0.56-2.21) 0.8 ** 0.22 (0.05-0.97) 0.03
AA - _ 82 0.92 (0.54-1.55) 0.7 ** _
¥ Unadjusted for multiple comparisons
*Statistical significance with Bonferroni correction (a/n = 0.05/29) p-value ≤ 0.002
Hung et al. BMC Medical Genetics 2011, 12:65
http://www.biomedcentral.com/1471-2350/12/65
Page 5 of 10in the model for the SNP rs2808630 and CKD included
age 1.05 (1.03,1.07), hypertension 2.21 (1.33, 3.08) and dia-
betes 2.44 (1.11, 5.35). History of cardiovascular disease
1.42 (0.66,3.0.8), obesity 0.77 (0.48,1.25), LDL cholesterol
mg/dL 1.0 (0.9, 1.01), smoking 1.11 (0.63, 1.97) and CRP
levels (mg/dL) 0.96 (0.81, 1.14) were not independent pre-
dictor in this model.
In contrast, rs3093058 was associated with a decreased
risk of CKD in the unadjusted analysis [AG vs. AA gen-
otype, 0.76 (95% CI 0.60-0.96; p = 0.02)] (table 3). How-
ever, this association was not significant after Bonferroni
adjustment or after adjustment for known risk factors
for CKD. None of the other SNPs were associated with
the risk of CKD in African Americans. There was no
association observed between the studied SNPs and
CKD in non-Hispanic whites or Mexicans Americans.
CRP genotypes and continuous GFR by MDRD equation
We examined the association between the selected CRP
SNPs and continuous eGFR. There was no association
detected with continuous eGFR and the tested CRP
SNPs in the unadjusted or fully adjusted model (table
5). Additional unadjusted logistic regression for low
eGFR (GFR < 60 ml/min) was performed as an alterna-
tive analysis for all CRP SNPs with no association
detected (data not shown).
CRP genotypes and albuminuria
We further evaluated the association between the CRP
SNPs with albuminuria (any degree of albuminuria
versus none). The rs2808630 SNP was the only CRP
SNP significantly associated with albuminuria in non-
Hispanic blacks. To examine the association of the
rs2808630 with albuminuria, we adjusted all our models
for eGFR. In the minimally adjusted analysis (model 1),
the AG genotype had an OR 1.68 (95% CI 1.27-2.23; p
= 0.0009) for the presence of albuminuria compared to
the AA genotype. Similarly, the AG genotype of
rs2808630 was associated with albuminuria in the fully
adjusted model with an OR of 3.07 (95%CI 1.59-5.94; p
= 0.002) compared to the AA genotype (table 6). These
associations were significant after Bonferroni adjustment
(p ≤ 0.002). Other independent predictors in the model
for the SNP rs2808630 and albuminuria included age
(years) 1.03 (1.01,1.06), hypertension 2.42 (1.35, 4.35)
and diabetes 2.52 (1.12, 5.67). History of cardiovascular
disease 1.47 (0.67, 3.26), body mass index(BMI) greater
than thirty 0.82 (0.46, 1.41), LDL cholesterol mg/dL 1.0
(0.99, 1.00), smoking 1.18 (0.67, 2.06) and CRP levels
(mg/dL), 1.24 (0.90, 1.70) were not independent predic-
tor in this model. There was no association observed
between the studied SNPs and albuminuria in non-His-
panic whites or Mexicans Americans.
There were no statistically significant differences in
the demographics or clinical characteristics among the
different rs2808630 genotypes (table 7).
Discussion
In this nationally-representative population, we show an
association between the CRP SNP rs2808630 and the
Table 4 Adjusted and weighted association between CRP polymorphism rs2808630 and rs3093058 and CKD in African
Americans Participants
Models Genotype OR 95% CI ¥ p-value
rs2808630
Fully adjusted model AA ref**
AG 2.94 1.61, 5.38 0.001*
GG 2.22 0.68, 7.23 0.2
Fully adjusted model plus Log transformed CRP AA ref**
AG 3.09 1.65, 5.80 0.001*
GG 2.41 0.79, 7.39 0.1
rs3093058
Fully adjusted model AA ref**
AT 0.44 0.49,1.44 0.5
TT 0.15 0.02, 1.36 0.09
Fully adjusted model plus Log transformed CRP AA ref**
AT 0.8 0.45, 1.41 0.4
TT 0.15 0.02,1.39 0.09
¥ Unadjusted for multiple comparisons
*Statistical significance with Bonferroni correction (a/n = 0.05/29) p-value ≤ 0.002
Number of participants by rs2808630 genotype: AA = 1131; AG 419, and GG = 34
**ref. reference group homozygous for the major allele.
Fully adjusted model: adjusted for age, sex, diabetes, hypertension, cardiovascular disease, BMI, smoking and LDL cholesterol
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defined either by low GFR < 60 ml/min or the presence
of albuminuria. This result is concordant with the find-
ings of our previous study in which rs2808630 was asso-
ciated with CKD progression in a longitudinal
prospective CKD cohort from the African American
Study of Kidney Disease and Hypertension[11].
CKD is multifactorial, occurring in the context of
chronic co-morbid conditions such as diabetes mellitus,
cardiovascular disease, obesity and hypertension. Since
all of these conditions impact vascular inflammation,
C K Di sc o n s i d e r e da sa ni nflammatory condition
[12,30]. Based on these observations, one can speculate
that individuals prone to a higher inflammatory
Table 5 Association between CRP variants and eGFR-MDRD
linear regression to eGFR (log transformed) for each SNP
Non-Hispanic Whites Non-Hispanic Blacks Mexican Americans
b(95% CI) ¥ p-value b (95% CI) ¥ p-value b(95% CI) ¥ p-value
rs2808630
Unadjusted -0.001 (-0.02, 0.01) 0.55 -0.01 (-0.04,0.02) 0.61 -0.01 (-0.01, 0.03) 0.54
Fully adjusted -0.01 (-0.04, 0.02) 0.46 0.00 (-0.04, 0.04) 0.94 0.01 (-0.01, 0.04) 0.20
rs1205
Unadjusted -0.001 (-0.02, 0.01) 0.76 -0.01 (-0.03, 0.02) 0.53 -0.001(-0.01, 0.02) 0.55
Fully adjusted -0.001 (-0.02, 0.02) 0.84 -0.01 (-0.04, 0.01) 0.32 0.01 (-0.02, 0.04) 0.55
rs1417938
Unadjusted 0.001 (-0.02, 0.02) 0.72 -0.01(-0.04, 0.02) 0.54 -0.01 (-0.03, 0.01) 0.51
Fully adjusted 0.01 (-0.01, 0.03) 0.35 -0.02 (-0.05, 0.01) 0.18 -0.001(-0.03, 0.03) 0.84
rs1800947
Unadjusted -0.001 (-0.05, 0.04) 0.87 0.01 (-0.13, 0.16) 0.84 0.03 (- 0.02, 0.07) 0.26
Fully adjusted 0.01(-0.07, 0.09) 0.75 0.04 (-0.20, 0.27) 0.75 0.01 (-0.04, 0.06) 0.72
rs3093058
Unadjusted -0.08 (-0.31, 0.14) 0.45 0.01 (-0.01, 0.04) 0.36 0.01 (-0.05, 0.06) 0.78
Fully adjusted -0.04 (-0.13, 0.05) 0.36 -0.01 (-0.04, 0.02) 0.63 -0.03 (-0.11, 0.04) 0.34
rs3093066
Unadjusted 0.02 (-0.19, 0.23) 0.86 0.02 (-0.01, 0.04) 0.16 -0.03 (-0.09, 0.03) 0.37
Fully adjusted 0.06 (-0.13, 0.25) 0.53 0.01 (-0.02, 0.03) 0.68 -0.01 (-0.11, 0.08) 0.78
¥ Unadjusted for multiple comparisons
Fully adjusted: age, gender, diabetes, hypertension, cardiovascular disease, BMI, smoking, LDL cholesterol, log transformed C reactive protein and albuminuria
Table 6 Adjusted and weighted association between CRP polymorphism rs2808630 and albuminuria in African
Americans Participants
Models Genotype OR 95% CI ¥ p-value
rs2808630
Adjusted for Age and gender (Model 1). AA ref*
AG 1.68 1.27, 2.23 0.0009
GG 0.99 0.47, 2.28 0.9
Adjusted for risk factors AA ref*
AG 2.95 1.54, 5.67 0.002
GG 1.78 0.50, 76.34 0.4
Adjusted for risk factors and Log transformed CRP (Model 2). AA ref*
AG 3.07 1.59, 5.94 0.002
GG 1.91 1.00, 6.54 0.3
*ref. reference group homozygous for the major allele.
¥ Unadjusted for multiple comparisons
* Statistical significance with Bonferroni correction (a/n = 0.05/29) p-value ≤ 0.002
Odd ratios are adjusted for:
Model 1: adjusted for age, sex and GFR.
Model 2: age, gender, diabetes, hypertension, cardiovascular disease, BMI, cotinine levels, NSAIDS exposure, LDL cholesterol, GFR and log transformed C reactive
protein.
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higher risk of CKD progression. However, our current
and previous study showed that the minor allele of SNP
rs2808630, which is associated with lower CRP levels in
the general population (18, 26, 20, 21), is associated
with CKD, now in two independent cohorts[11] along
with another replication study [31]. The association
between rs2808630 and CKD status remained significant
after adjustment for CRP levels, suggesting that the
pathway for this association is not mediated by CRP. On
the other hand, it may be related to other immune-
modulatory molecules of the cytokine network, which
involves a highly complex interaction of multiple cas-
cades of gene activation and suppression [32].
Another possible explanation for our observations is
that the association between inflammation and CKD is
the consequence of the multiple co-morbidities and
decreased clearance from the kidney. This might suggest
that the inflammatory response itself may not be related
to a genetic predisposition towards disease progression
in kidney disease. It is also possible that the rs2808630
is in linkage disequilibrium with another SNP that
increases the risk of CKD. CRP rs2808630 is located in
the 3’ flanking region of the gene and is not in strong
linkage disequilibrium with any common variation
found within 50 kb in the Yoruba International HapMap
dataset, although it is in moderate LD (r
2~0.5) with
three intergenic common SNPs [33]. We cannot rule
out the possibility that other common SNP(s) outside
the 50 kb boundary may be in LD with rs2808630 or
that a less common SNP (in the 1%-5% range) is in LD
with rs2808630. After a preliminary exploration of the
newly released 1000 Genomes Project Data for Yoruba
[34] the latter possibility seems unlikely (data not
shown).
In order to better understand the association of CRP
rs2808630 with CKD, we studied the association of the
rs2808630 with albuminuria and with continuous eGFR
as independent outcomes. CRP rs2808630 was also asso-
ciated with albuminuria. Albuminuria is a strong risk
factor for CKD progression and could potentially repre-
sent a pathway for the association with CKD progres-
sion. Although genetic basis for GFR traits [35](9) and
albuminuria traits [36,37] have been recently identified
and may differ, it has been recently highlighted that
information regarding albuminuria should be incorpo-
rated in the CKD staging system in order to be able to
predict those at risk for progression [27]. This relevant
clinical observation highlights that gene variants asso-
ciated with albuminuria may be part of the common
pathway for CKD progression and underscores the need
to include albuminuria in the outcome when studying
genetic susceptibility for CKD progression through com-
mon pathways.
Finally, individuals with this CRP genotype may
respond less to other interventions compared with
patients that have the referent genotypes at these SNPs.
Our previous study findings in the AASK trial suggested
that African Americans with the minor allele for the
rs2808630 benefited less from ACE inhibition. Unfortu-
nately, NHANES III lacks detailed medication data, and
we were not able to test for this association.
Recently, genome-wide association studies (GWAS) stu-
dies have identified a number of potential candidate genes
and genomic regions that may contribute to the pathogen-
esis of CKD(9, 10, 12). Two important susceptibility genes
for CKD progression to ESRD have been identified in Afri-
can Americans for “non-diabetic kidney disease”[10].
These include MYH9 [9] and APOL1 [10]. In addition to
the genes implicated in CKD progression to ESRD, GWAS
meta-analyses has also yielded a large number of potential
gene variants that are associated with both creatinine-
based and cystatin C-based eGFR[35]. However, taken all
together, these SNPs explain only about 1.43% of the GFR
variability at the population level, suggesting that many
other genetic components of kidney function remain to be
Table 7 Clinical Characteristics of African American Participants of the NHANES III Genetic Study (1991-1994) by
rs2808630 genotype
AA (n = 1131) AG (n = 416) GG (n = 34) p-value
Age, years, median (IQR) 33 (20,46) 34 (22,47) 38(29,55) 0.2
Gender, male (%) 43 42 50 0.9
Hypertension (%) 23 24 29 0.3
Diabetes (%) 9 11 * (*) 0.6
Cardiovascular Disease (%) 6 5 * (*) 0.8
Serum Creatinine, mg/dL (calibrated) 1.1 (0.9,1.2) 1 (0.9,1.2) 1.1 (1, 1.2) 0.39
Urine albumin to creatinine ratio 4.7 (2.2, 104) 5.2 (2.3, 15) 6.9 (3.4, 25) 0.03
Body Mass Index Kg/m2 26 (22, 30) 26 (22, 32) 26 (22, 32) 0.06
LDL cholesterol, mg/dL 121 (98, 145) 115 (95, 142) 100 (80, 169) 0.9
Smoking (%) 37 38 38 0.8
Categorical variables were tested using the Cochran-Mantel-Haenszel Test and continuous variables were Tested using the Taylor linearization method in
SUDAAN with all analysis weighed.
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Page 8 of 10identified. Furthermore it has been hypothesized that there
are genes involved in disease initiation only (i.e UMOD)
[35] and other genes involved in progression to ESRD.
The main strength of this study is that it is performed
in a large population-based, nationally representative
and ethnically diverse sample, which is rich in phenoty-
pic information, allowing us to adjust in our analysis for
the main risk factors known to be associated with CKD
progression. However, our study is not without limita-
tions. NHANES III is a population based sample
designed to represent the health status of the non-insti-
tutionalized US population which follows a cross-sec-
tional design and precludes the possibility of studying
gene effect on disease progression. Secondly, eGFR was
calculated using a single creatinine measurement. Given
some variability involved in the measurement, a single
value may increase the risk of misclassification of parti-
cipants without CKD as CKD and overall dilute the
association. Thirdly, because this is a population-based
sample, the majority of the participants had normal kid-
ney function (mean GFR 95 ± 25 ml/min) and only 7%
had low eGFR, with the vast majority of them classified
as stage 3. This may have limited our ability to detect
an association with eGFR. In contrast, our previous
study [11] was performed in a population of only Afri-
can Americans, all of whom had established CKD (mean
baseline GFR 43 47 ± 13.5 ml/min) followed logintudin-
ally and with repeated measurements of the outcome
using the gold standard to measure GFR (iothalamate I-
125). Overall, these two studies are complementary to
each other (a comparison of the difference between
populations studies, design and outcome ascertaiment
between AASK and NHANES is provided in our addi-
tional file1 tables S2 and S3). The fact that we were able
to demonstrate an association with albuminuria is also
highly relevant as this may potentially explain the rela-
tionship with CKD progression via a common pathway.
Conclusion
The CRP gene variant rs2808630 was associated with
the presence of CKD in non-Hispanic black participants.
Larger longitudinal studies of individuals with estab-
lished CKD are needed to further evaluate the role of
CRP polymorphisms in CKD progression in an ethni-
cally diverse population, including non-Hispanic whites
and Mexican Americans. Further studies are also
required to evaluate if this association is with CKD in
general or with specific disease etiologies such as dia-
betes and hypertension. Finally, pharmacogenetic studies
evaluating the role of CRP polymorphisms in the
response to specific medications such as ACE inhibition
with regards to renoprotection are also needed.
Additional material
Additional file 1: Table S1; Clinical characteristics by CKD status and
by race/ethnicity. This table compares the clinical characteristics of
individuals with and without CKD by race group. Table S2: Comparison
in the study design, population and outcome ascertainment between
NHANES III DNA bank (1991-1994) and the African American Study in
Kidney Disease and Hypertension. This table provides a comparison of
NHANES III DNA subgroup and the AASK trial. Table S3: Clinical
characteristics of the AASK participants by rs2808630 genotypes This
table provides the clinical characteristics by rs2808630 by genotype for
the AASK participants Table S4: CRP polymorphisms, genotypes and
weighed frequencies for all participants with and without albuminuria
Genotype frequencies by race and by albuminuria status for all genotype
SNPs.
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